Literature DB >> 17197373

The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

John H Krystal1, D Cyril D'Souza, Jürgen Gallinat, Naomi Driesen, Anissa Abi-Dargham, Ismene Petrakis, Andreas Heinz, Godfrey Pearlson.   

Abstract

Individuals with schizophrenia are at increased risk for developing substance abuse disorders. Here, we consider factors that might elevate their risk for substance abuse. The tendency among schizophrenic individuals to overvalue drug-like rewards and to devalue the potential negative consequences of substance abuse may be a contributing factor to their substance abuse risk. This bias, which may partly reflect the convergence of glutamatergic and dopaminergic input to the limbic striatum, also may contribute to disadvantageous decision-making and other impulsive behavior. This propensity to seek drug-like rewards is augmented by alterations in nicotinic cholinergic, GABAergic, glutamatergic, and cannabinnoid receptor function associated with schizophrenia that increase the abuse liability of low doses of nicotine, ethanol, and perhaps cannabis, and augment the dysphoric effects of higher doses of ethanol and cannabis. The distortions in reward processing and altered response to substances of abuse also increase the likelihood that individuals with schizophrenia will self-medicate their subjective distress with abused substances. The focus on distinctions between motivation and reward with respect to substance abuse risk by schizophrenic patients suggests a need for a reconsideration of the construct of "negative symptoms" for this dually-diagnosed patient group.

Entities:  

Mesh:

Year:  2006        PMID: 17197373     DOI: 10.1007/bf03033360

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  160 in total

1.  Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London.

Authors:  P J Duke; C Pantelis; M A McPhillips; T R Barnes
Journal:  Br J Psychiatry       Date:  2001-12       Impact factor: 9.319

2.  Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol.

Authors:  Roberto I Melendez; Zachary A Rodd-Henricks; Eric A Engleman; Ting-Kai Li; William J McBride; James M Murphy
Journal:  Alcohol Clin Exp Res       Date:  2002-03       Impact factor: 3.455

3.  Smoking and schizophrenia: abnormal nicotinic receptor expression.

Authors:  S Leonard; C Breese; C Adams; K Benhammou; J Gault; K Stevens; M Lee; L Adler; A Olincy; R Ross; R Freedman
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

4.  Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input.

Authors:  P O'Donnell; A A Grace
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

5.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

6.  Decision-making and addiction (part II): myopia for the future or hypersensitivity to reward?

Authors:  Antoine Bechara; Sara Dolan; Andrea Hindes
Journal:  Neuropsychologia       Date:  2002       Impact factor: 3.139

7.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.

Authors:  Ismene L Petrakis; Stephanie O'Malley; Bruce Rounsaville; James Poling; Colette McHugh-Strong; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

9.  Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study.

Authors:  K S Kendler; M McGuire; A M Gruenberg; D Walsh
Journal:  Am J Psychiatry       Date:  1995-05       Impact factor: 18.112

10.  Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness.

Authors:  K S Kendler; C C Masterson; K L Davis
Journal:  Br J Psychiatry       Date:  1985-11       Impact factor: 9.319

View more
  28 in total

1.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

2.  Altered Global Signal Topography in Schizophrenia.

Authors:  Genevieve J Yang; John D Murray; Matthew Glasser; Godfrey D Pearlson; John H Krystal; Charlie Schleifer; Grega Repovs; Alan Anticevic
Journal:  Cereb Cortex       Date:  2017-11-01       Impact factor: 5.357

3.  Biologic Commonalities between Mental Illness and Addiction.

Authors:  Karen J Hartwell; Bryan K Tolliver; Kathleen T Brady
Journal:  Prim psychiatry       Date:  2009-08-01

Review 4.  GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies.

Authors:  Marisa M Silveri
Journal:  Pharmacol Ther       Date:  2014-03-11       Impact factor: 12.310

5.  Do reward-processing deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of physiological response to natural rewards and drug cues.

Authors:  Clifford M Cassidy; Mathieu B Brodeur; Martin Lepage; Ashok Malla
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

Review 6.  Clinical and pathological features of alcohol-related brain damage.

Authors:  Natalie M Zahr; Kimberley L Kaufman; Clive G Harper
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

7.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

Review 8.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

9.  Hypofrontality and Posterior Hyperactivity in Early Schizophrenia: Imaging and Behavior in a Preclinical Model.

Authors:  Gen Kaneko; Basavaraju G Sanganahalli; Stephanie M Groman; Helen Wang; Daniel Coman; Jyotsna Rao; Peter Herman; Lihong Jiang; Katherine Rich; Robin A de Graaf; Jane R Taylor; Fahmeed Hyder
Journal:  Biol Psychiatry       Date:  2016-05-30       Impact factor: 13.382

10.  Amygdala connectivity differs among chronic, early course, and individuals at risk for developing schizophrenia.

Authors:  Alan Anticevic; Yanqing Tang; Youngsun T Cho; Grega Repovs; Michael W Cole; Aleksandar Savic; Fei Wang; John H Krystal; Ke Xu
Journal:  Schizophr Bull       Date:  2013-12-22       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.